Streptococcus pneumoniae serotype 19A (S. pneumoniae 19A)

Streptococcus pneumoniae serotype 19A is a bacterial strain defined by its unique capsular polysaccharide structure among over one hundred known S. pneumoniae serotypes. It is not a single molecule or receptor but rather a clinically significant variant responsible for both mucosal and invasive diseases such as otitis media, bacteremia, meningitis, and especially severe forms of community-acquired pneumonia. Serotype 19A gained global prominence after the introduction of the heptavalent pneumococcal conjugate vaccine (PCV7), which did not include this serotype—leading to increased prevalence through "serotype replacement." This strain is notable for its high rates of antimicrobial drug resistance, particularly against penicillins, macrolides like erythromycin, tetracyclines, and sulfonamides. Resistance mechanisms include alterations in penicillin-binding proteins as well as acquisition of macrolide-resistance genes mefE and ermB. The introduction of broader-spectrum vaccines such as PCV13—which includes coverage against serotype 19A—has led to significant reductions in disease incidence from this variant in many regions; however, ongoing surveillance remains critical due to its genetic diversity and capacity for further evolution under selective pressures from vaccination programs. Because "Streptococcus pneumoniae serotype 19A" refers to an entire bacterial lineage rather than a discrete molecular target like an enzyme or receptor protein typically considered druggable targets in pharmacology or biotechnology contexts—it should not be classified as a therapeutic target per se but rather as an important pathogen with major implications for infectious disease management strategies.

Other names

Pneumococcus serotype 19AS. pneumoniae type 19AStreptococcus pneumoniae type 19A

For antibiotics: Inhibition of cell wall synthesis or protein synthesis; however, many strains are multidrug resistant due to genetic mutations in penicillin-binding proteins and acquisition of resistance genes such as mefE and ermB. For vaccines: Induction of serotype-specific immunity via capsular polysaccharide antigens included in conjugate vaccines; PCV13 directly targets the capsule polysaccharide unique to serotype 19A.